However, the medical agents currently available for controlling hypercortisolism and targeting corticotroph pituitary tumours, adrenal glands, or glucocorticoid receptors are effective in subsets of patients with CS [3, 4]. This evidence concerns the gene NR3C1 and Cowden syndrome 1.